New lipid nanocapsules exhibit sustained release properties for amiodarone.
Amiodarone is widely used in heart diseases but also provokes severe adverse effects due to its accumulation in other tissues than the heart. In order to circumvent side effects colloidal drug carriers have been designed to deliver the drug specifically to the site of action. Many preparation methods have been described and most have been reported to involve a high initial drug loss when introduced in an aqueous environment. Lipid nanocapsules (LNC) were prepared by a new phase inversion procedure and characterized in terms of size, surface potential, encapsulation efficiency, and drug release pattern. The encapsulation rate was varying between 92 and 94%. LNC did not display a distinct initial burst effect while the drug release of amiodarone can be prolonged over a significant period. Acceptor phase interfaces such as liposomes or blank LNC were applied to the release medium to enable a drug release to larger extents. The release was triggered by the pH of the release medium showing a faster release for lower pH; t(50%) values vary from 25.6 h (pH 2) to 236.3 h (pH 7.4). Moreover, LNC were prepared of different sizes (24.7+/-2.0 to 102.5+/-0.9 nm) showing only slight influences on their drug release profiles. It was concluded that the LNC surface is able to retain amphiphilic drugs. Such properties could allow drug delivery to the site of action without high initial drug loss.
Lamprecht
Alf
A
INSERM ERIT-M 0104 (Ingénierie de la Vectorisation Particulaire), Immeuble IBT, Université d'Angers, 10 rue André Boquel, France.
Bouligand
Yves
Y
Benoit
Jean-Pierre
JP
D000638:Amiodarone / Q000008:administration & dosage* / Q000737:chemistry; D002152:Calorimetry, Differential Scanning; D002214:Capsules; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003692:Delayed-Action Preparations; D004563:Electrochemistry; D004655:Emulsions; D005079:Excipients; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D019344:Lactic Acid; D008055:Lipids; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D012995:Solubility; D013696:Temperature; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000737:chemistry
D002214:Capsules; D003692:Delayed-Action Preparations; D004655:Emulsions; D005079:Excipients; D008055:Lipids; D011108:Polymers; D014665:Vasodilator Agents; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D000638:Amiodarone